Late-pregnancy oxytocin alleviates neuroinflammation and hyperalgesia in chronic migraine model rats
Background
Migraine is a debilitating primary neurological disorder, disproportionately affecting women, with symptoms often changing across hormonal transitions. While many female migraine patients experience significant relief during late pregnancy, the underlying mechanisms are poorly understood, and suitable animal models for investigating migraine during pregnancy have been lacking. This gap hinders the development of targeted therapies that leverage natural physiological changes. Understanding the role of specific neuropeptides like oxytocin in this phenomenon could unlock novel therapeutic strategies.
Study Design
Researchers established a pregnant chronic migraine rat model. They investigated endogenous oxytocin (OT) expression in the paraventricular nucleus (PVN) and nucleus of the solitary tract (NTS). To test therapeutic potential, rats received repeated intranasal OT administration or AAV9-mediated OT overexpression directly into the PVN or NTS. Primary endpoints included measuring CGRP expression, neuronal activation, and pro-inflammatory cytokine levels (IL-1α, IL-1β, IL-6, TNF-α) in the NTS, alongside assessing hyperalgesic behaviors.
Results
Oxytocin (OT) expression was markedly upregulated in both the PVN and NTS during late pregnancy in the migraine model. Viral tracing confirmed direct oxytocinergic axonal projections from the PVN to the NTS. Both repeated intranasal OT administration and AAV9-mediated OT overexpression in either the PVN or NTS significantly reduced CGRP expression, neuronal activation, and pro-inflammatory cytokine levels (IL-1α, IL-1β, IL-6, TNF-α) within the NTS. These interventions also alleviated hyperalgesic behaviors in the chronic migraine rats. Further mechanistic investigations demonstrated that OT mediated these protective effects by downregulating the extracellular matrix (ECM)-receptor interaction signaling pathway and integrin receptor expression. This suggests a novel pathway for migraine relief.
Elevated endogenous OT during late pregnancy alleviated neuroinflammation and hyperalgesic behaviors through regulation of the
ECM-receptor interaction signaling pathway.
Key Findings
- Oxytocin (OT) expression was markedly upregulated in
PVNandNTSduring late pregnancy in migraine rats. - Oxytocinergic projections from
PVNtoNTSwere confirmed. - Intranasal OT or
AAV9-mediated OT overexpression significantly reducedCGRPexpression and neuroinflammation inNTS. - OT administration alleviated hyperalgesic behaviors in chronic migraine rats.
- OT's protective effects were mediated by downregulating
ECM-receptor interaction signalingandintegrin receptor expression.
Why It Matters
This study provides crucial mechanistic insights into why migraine symptoms often improve during late pregnancy, pointing to oxytocin as a key mediator. For peptide users and clinicians, this research highlights oxytocin as a potential therapeutic agent for chronic migraine, particularly in women. The use of intranasal administration suggests a non-invasive delivery route that could be translated to human protocols. While still in preclinical stages, these findings lay a foundation for developing oxytocin-based therapeutic strategies for migraine, potentially offering a novel approach to managing this debilitating condition by targeting neuroinflammation and pain pathways.
oxytocin
migraine
neuroinflammation
hyperalgesia
pregnancy
preclinical-animal